Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. hbmp-700

HbMP-700

The World's First Safe and Efficacious Human Blood Substitute: HbMP-700, a Haemoglobin based oxygen carrier, based on bovine blood.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 HbMP-700 project word cloud

Explore the words cloud of the HbMP-700 project. It provides you a very rough idea of what is the project "HbMP-700" about.

critical    shortages    business    patient    safety    source    technological    conflicts    develops    malignancies    severe    red    conduct    unlimited    annually    weeks    standard    25    frequent    bears    purification    infection    global    risk    transformed    bovine    manufacturing    types    contamination    clinical    total    excellent    rbc    adding    15nb    peak    conducting    few    countries    victims    demand    powder    voluntary    accidents    85    preclinical    plan    representing    sufficient    patented    first    substitute    sales    feasibility    35    extracted    stored    match    slaughterhouse    disasters    gcp    afford    lyophilized    good    markets    donors    care    market    sme    compensate    human    transfusions    proof    world    blood    introduction    leads    trial    natural    healthcare    regulatory    laboratory    months    situation    ery    haematological    subsequently    bn    military    trials    nearly    cc    700    gmp    compliant    treat    mio    hbmp    economic    patients    humans    surgery    donor    infections    cell    supply   

Project "HbMP-700" data sheet

The following table provides information about the project.

Coordinator		 CC-ERY GMBH 

Organization address
address: ROBERT-ROSSLE-STRASSE 10
city: BERLIN
postcode: 13125
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Project website http://www.cc-ery.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CC-ERY GMBH DE (BERLIN) coordinator 50˙000.00

Map

 Project objective

CC-Ery GmbH develops HbMP-700, the world’s first substitute for human blood as a source for red blood cell (RBC) transfusions. 85 Mio. RBC transfusions are used p.a., representing a 10-15nb€ market. They are used to compensate for blood loss during surgery, treat patients with haematological malignancies, as well as victims of accidents, natural disasters, and military conflicts. The only source for RBC transfusions today are voluntary human blood donors. This leads to frequent supply shortages in the EU and other major healthcare markets. Donor blood must match patient blood. It can only be stored a few weeks, adding to the critical supply situation. Developing countries face a more severe situation as they cannot afford the standard of care of the developed world. In addition, human blood bears the risk of contamination with infections. HbMP-700 is extracted from bovine blood – a nearly unlimited, low cost supply source. It is transformed by a patented purification and manufacturing method to a lyophilized powder that is as effective as RBC transfusions from human blood, but bears no risk of infection, can be stored for months, and can be given to patients of all blood types. Bovine blood from one major EU slaughterhouse is sufficient to produce enough HbMP-700 to supply global demand for RBC transfusions. CC-Ery implemented the manufacturing method on a laboratory scale and is currently conducting preclinical trials, so far with excellent results. The objective of the SME Phase I project is to develop a business plan for the market introduction of HbMP-700. For this, a technological, regulatory, and economic feasibility analysis will be conducted. In Phase II, it is planned to build up a GMP (Good Manufacturing Practice) compliant manufacturing process and subsequently conduct a GCP (Good Clinical Practice) safety and proof of concept trial in humans. Total cost to market is estimated to be € 25-35 Mio. Peak sales are estimated to be more than € 1 bn. annually.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HBMP-700" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HBMP-700" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More